iRhythm Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From iRhythm Technologies, Inc.
Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.
Cardio Conversations: iRhythm Prepares To Deliver ‘Standard-Of-Care’ Cardiac Monitoring
Quentin Blackford, CEO of iRhythm, talked to Medtech Insight about his company’s plans to bring its Zio long-term cardiac monitoring platform to more patients by building its evidence base and marketing in more countries outside the US.
News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use
This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.
News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More
News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.